Micro- and nanocarrier-mediated lung targeting

Expert Opinion on Drug Delivery

Volumn 7, Issue 7, 2010, Pages 781-794

  Kurmi, Balak D ^a   Kayat, Jitendra ^a   Gajbhiye, Virendra ^a   Tekade, Rakesh K ^a   Jain, Narendra K ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Dendrimers; Liposomes; Lung targeting; Microspheres; Nanocarriers; Nanoparticles

Indexed keywords

BUDESONIDE; CISPLATIN; DENDRIMER; DOXORUBICIN; DRUG CARRIER; ENROFLOXACIN; GEMCITABINE; ISONIAZID; ITRACONAZOLE; LIPOSOME; MICROSPHERE; NANOCARRIER; NANOPARTICLE; NIOSOME; POLOXAMER; POLYSORBATE 80; PYRAZINAMIDE; RIFAMPICIN; RUBITECAN; TERBUTALINE SULFATE; TUBERCULOSTATIC AGENT;

AREA UNDER THE CURVE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TARGETING; DRUG UPTAKE; HUMAN; LUNG ALVEOLUS; LUNG ALVEOLUS MACROPHAGE; LUNG CANCER; NONHUMAN; REVIEW; SUSTAINED DRUG RELEASE; DRUG EFFECTS; LUNG; NANOTECHNOLOGY;

DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG; MICROSPHERES; NANOPARTICLES; NANOTECHNOLOGY;

EID: 77953862482     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2010.492212     Document Type: Review

References (124)

1. Azarmi S, Roa WH, Lobenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev 2008;60:863-875
2. Banov CH. Anatomy and physiology of the lower and upper airway. J Allergy Clin Immunol 1989;84:1044-1046
3. Wolfson MR, Shaffer TH. Respiratory physiology: structure, function, and integrative responses to intervention with special emphasis on the ventilatory pump. Cardiopulm Phys Ther 2004;4:40
4. Patton JS, Platz RM. Pulmonary delivery of peptides and proteins for systemic action. Adv Drug Deliv Rev 1992;8:179-196
5. Clark A. Formulation of proteins and peptides for inhalation. Drug Deliv Systems Sci 2002;2:73-77
6. Courrier HM, Butz N, Vandamme TF. Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug Carr Syst 2002;19:425-498
7. Gill S, Lobenberg R, Ku T, et al. Nanoparticles: characteristics, mechanisms of action and toxicity in pulmonary drug delivery-a review. J Biomed Nanotechnol 2007;3:107-119
8. Ranney DF. Drug targeting to the lungs. Biochem Pharmacol 1986;35:1063-1069
9. Raeburn D, Underwood SL, Villamil ME. Techniques for drug delivery to the airways, and the assessment of lung function in animal models. J Pharmacol Toxicol Methods 1992;27:143-159
10. Thompson DC. Pharmacology of therapeutic aerosols. Marcel Dekker, New York; 1992
11. Byron PR. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci 1986;75:433-438
12. Burton A, Schanker LS. Absorption of corticosteroids from the rat lung. Steroids 1974;23:617-624
13. Brown RA, Schanker LS. Absorption of aerosolized drugs from the rat lung. Drug Metab Dispos 1983;11:355-360
14. Smolensky MH, D'Alonzo GE, Kunkel G, et al. Day-night patterns in bronchial patency and dyspnoea: basis for one daily and unequally divided twice daily dosing schedules. Chronobiol Int 1987;4:303-307
15. Barnes PJ. Nocturnal asthma: mechanisms and treatment. Br Med J 1984;12:1397-1398
16. Surendrakumar K, Martyn GP, Hodgers ECM, et al. Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J Control Release 2003;91:385-394
17. Cook RO, Pannu RK, Kellaway IW. Novel sustained release microspheres for pulmonary drug delivery. J Control Rel 2005;104:79-90
18. Zeng XM, Martin GP, Marriott C. The controlled delivery of drugs to the lung. Int J Pharm 1995;124:149-164
19. Hardy JG, Chadwick TS. Sustained release drug delivery to the lungs. Clin Pharmacokinet 2000;39:1-4
20. Ventura CA, Tommasini S, Crupi E, et al. Chitosan microspheres for intrapulmonary administration of moxifloxacin: interaction with biomembrane models and in vitro permeation studies. Eur J Pharm Biopharm 2008;68:235-244
21. Makino K, Yamamoto N, Higuchi K, et al. Phagocytic uptake of polystyrene microspheres by alveolar macrophages: effects of the size and surface properties of the microspheres. Colloids Surf Biointerfaces 2003;27:33-39
22. Huo D, Deng S, Li L, et al. Studies on the poly(lactic-co-glycolic) acid microspheres of cisplatin for lung-targeting. Int J Pharm 2005;289:63-67
23. Lu B, Zhang JQ, Yang H. Lung-targeting microspheres of carboplatin. Int J Pharm 2003;265:1-11
24. Yang Y, Bajaj N, Xu P, et al. Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials 2009;30:1947-1953
25. Schroder J. Enrofloxacin: a new antimicrobial agent. J S Af Vet Assoc 1989;60:122-124
26. Prescott JF, Yielding KM. In vitro susceptibility of selected veterinary bacterial pathogens to ciprofloxacin, enrofloxacin and norfloxacin. Can J Vet Res 1990;54:195-197
27. Hannan PCT, Windsor GD, Jong A, et al. Comparative susceptibilities of various animal-pathogenic mycoplasmas to fluoroquinolones. Antimicrob Agents Chemother 1997;41:2037-2040
28. Bebear CM, Renaudin J, Charron A, et al. Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis. Antimicrobiol Agents Chemother 1999;43:954-956
29. Wu CC, Shryock TR, Lin TL, et al. Antimicrobial susceptibility of Mycoplasma hyorhinis. Vet Microbiol 2000;76:25-30
30. Gautier-Bouchardon AV, Reinhardt AK, Kobisch M, et al. In vitro development of resistance to enrofloxacin, erythromycin, tylosin, tiamulin and oxytetracycline in Mycoplasma gallisepticum, Mycoplasma iowae and Mycoplasma synoviae. Vet Microbiol 2002;88:47-58
31. Tang S, Zhou Y, Li R, et al. Pharmacokinetics and lung-targeting characterization of a newly formulated enrofloxacin preparation. J Vet Pharmacol Ther 2007;30:443-450
32. Suarez S, O'Hara P, Kazantseva M, et al. Respirable microspheres containing rifampicin for the treatment of tuberculosis: screening in an infections disease model. Pharm Res 2001;18:1315-1319
33. Makino K, Nakajima T, Shikamura M, et al. Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: effect of molecular weight and composition of PLGA on release of rifampicin. Colloids Surf Biointerfaces 2004;36:35-42
34. Sharma R, Saxena D, Dwivedi AK, et al. Inhalable microparticles containing drug combinations to target alveolar microphages for treatment of pulmonary tuberculosis. Pharm Res 2001;18:1405-1410
35. Schwartz YS, Dushikin MI, Vavilin VA, et al. Novel conjugate of moxifloxacin and carboxymethylated glucan with enhanced activity against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2006;50:1982-1988
36. Muttil P, Kaur J, Kumar K, et al. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur J Pharm Sci 2007;32:140-150
37. Carpenter ZK, Williamson ED, Jim E, et al. Mucosal delivery of microparticle encapsulated ESAT-6 induces robust cell-mediated responses in the lung milieu. J Control Rel 2005;104:67-77
38. Tomoda K, Makino K. Effects of lung surfactants on rifampicin release rate from monodisperse rifampicin-loaded PLGA microspheres. Colloids Surf B Biointerfaces 2007;55:115-124
39. Illum L, Davis SS, Wilson CG, et al. Blood clearance and organ deposition of intravenously administered colloidal particles. The effects of particle size, nature and shape. Int J Pharm 1982;12:135-146
40. Laurence DR, Bennett PN, Brown MJ. Clinical pharmacology. Churchill Livingstone, New York; 1997
41. Ozkan Y, Dkmen N, Isimer A, et al. Clarithromycin targeting to lung: characterization, size distribution and in vivo evaluation of the human serum albumin microspheres. Farmaco 2000;55:303-307
42. Shi R, Zhang J, Li C, et al. Emergency of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China: gyrA mutation analysis by denaturing HPLC and DNA sequencing. J Clin Micribiol 2006;44:4566-4568
43. Brown MB, Jones SA. Hyluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin. J Eur Acad Dermatol Venereol 2005;19:308-318
44. Pritchrad K, Lansley AB, Martin GP, et al. Evaluation of the bioadhesive properties of hyaluronan derivatives: detachment weight and mucociliary transport rate studies. Int J Pharm 1996;129:137-145
45. Vachon E, Martin R, Plumb J, et al. CD44 is a phagocytic receptor. Blood 2006;107:4149-4158
46. Cantor JO, Turino GM. Can exogenously administered hyaluronan improve respiratory function in patients with pulmonary emphysema. Chest 2004;125:288-292
47. Zhou A, Guo L, Tang L. Effect of an intrathoracic injection of sodium hyaluronic acid on the prevention of pleural thickening in excess fluid of tuberculous thoracic cavity. Clin Exp Pharmacol Physiol 2003;30:203-205
48. Hwang SM, Kim DD, Chung SJ, et al. Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis. J Control Release 2008;129:100-106
49. Ahuja S, Ashman J. Analytical profiles of drug substances. Academic Press, New York; 1990
50. Sahin S, Selek H, Ponchel G, et al. Preparation, characterization and in vivo distribution of terbutaline sulfate loaded albumin microspheres. J Control Release 2002;82:345-358
51. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol 2008;26:57-64
52. Betancourt T, Brown B, Peppas LB. Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomed 2007;2:219-232
53. Sutton D, Nasongkla N, Blanco E, et al. Functionalized micellar systems for cancer targeted drug delivery. Pharm Res 2007;24:1029-1046
54. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10:1451-1458
55. Montet X, Abou KM, Reynolds F, et al. Nanoparticle imaging of integrins on tumor cells. Neoplasia 2006;8:214-222
56. Flenniken ML, Liepold LO, Crowley BE, et al. Selective attachment and release of a chemotherapeutic agent from the interior of a protein cage architecture. Chem Commun 2005;4:447-449
57. Lowery AR, Gobin AM, Day ES, et al. Immunonanoshells for targetedphotothermal ablation of tumor cells. Int J Nanomed 2006;1:149-154
58. Bhadra D, Bhadra S, Jain S, et al. A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm 2003;257:111-124
59. Fawaz F, Bonini F, Guyot M, et al. Influence of poly(DL-lactide) nanocapsules on the biliary clearance and enterohepatic circulation of indomethacin in the rabbit. Pharm Res 1993;10:750-756
60. Gref R, Luck M, Quellec P, et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf Biointerfaces 2000;18:301-313
61. Otsuka H, Nagasaki Y, Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev 2003;55:403-419
62. Skelding AK, Barry DR, Shafren DR. Systemic targeting of metastasic human breast tumor xenografts by Coxsackievirus A21. Breast Cancer Res Treat 2009;113:21-30
63. Koyama S, Eihara T, Fukao K. Expression of intercellular adhesion molecule-1 (ICAM-1) during the development of invasion and/or metastasis of gastric carcinoma. J Cancer Res Clin Oncol 1992;118:609-614
64. Chittasupho C, Xie SX, Baoum A, et al. ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. Eur J Pharm Sci 2009;37:141-150
65. Tsenga CL, Wanga TW, Dongb GC, et al. Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. Biomaterials 2007;28:3996-4005
66. Brzoska M, Langer K, Coester C, et al. Incorporation of biodegradable nanoparticles into human airway epithelium cells-in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases. Biochem Biophys Res Commun 2004;318:562-570
67. Lherm C, Muller RH, Pusieux F, et al. Alkylcyanoacrylate drug carriers: II. cytotoxicity of cyanoacrylate nanoparticles with different alkyl chain length. Int J Pharm 1992;84:13-22
68. Nguyen J, Reul R, Betz T, et al. Nanocomposites of lung surfactant and biodegradable cationic nanoparticles improve transfection efficiency to lung cells. J Control Release 2009;140:47-54
69. Zou W, Liu C, Chen Z, et al. Studies on bioadhesive PLGA nanoparticles: a promising gene delivery system for efficient gene therapy to lung cancer. Int J Pharm 2009;370:187-195
70. Kawashima Y, Yamamoto H, Takeuchi H, et al. Pulmonary delivery of insulin with nebulized DL-lactide/ glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J Control Release 1999;62:279-287
71. Zhang Q, Shen Z, Nagai T. Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats. Int J Pharm 2001;218:75-80
72. Yamamoto H, Kuno Y, Sugimoto S, et al. Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J Control Release 2005;102:373-381
73. Vaughn JM, McConville JT, Burgess D, et al. Single dose and multiple dose studies of itraconazole Nanoparticles. Eur J Pharm Biopharm 2006;63:95-102
74. Pandey R, Sharma A, Zahoor A, et al. Poly (DL-lactide-co-glycolide) nanoparticlebased inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003;52:981-986
75. Pandey R, Zahoor A, Sharma S, et al. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis 2003;83:373-378
76. Sharma A, Sharma S, Khuller GK. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother 2004;54:761-766
77. Mykhaylyk O, Dudchenko N, Dudchenko A. Doxorubicin magnetic conjugate targeting upon intravenous injection into mice: high gradient magnetic field inhibits the clearance of nanoparticles from the blood. J Magn Magn Mater 2005;293:473-482
78. Wu T, Hua MY, Chen JP, et al. Effects of external magnetic field on biodistribution of nanoparticles: a histological study. J Magn Magn Mater 2007;311:372-375
79. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-497
80. Funaro A, Horenstein AL, Santoro P, et al. Monoclonal antibodies and therapy of human cancers. Biotechnol Adv 2000;18:385-401
81. Trail PA, Bianchi AB. Monoclonal antibody drug conjugates in the treatment of cancer. Curr Opin Immunol 1999;11:584-588
82. Trail PA, King HD, Dubowchik GM. Monoclonal antibody drug immunoconjugates. Cancer Immunol Immunother 2003;52:328-337
83. Lambert JM. Drug-conjugated monoclonal antibodies for treatment of cancer. Curr Opin Pharmacol 2005;5:543-549
84. Akasaka Y, Ueda H, Takayama K, et al. Preparation and evaluation of bovine serum albumin nanospheres coated with monoclonal antibodies. Drug Design Deliv 1988;3:85-97
85. Hattori Y, Kawakami S, Nakamura K, et al. Efficient gene transfer into macrophages and dendritic cells by in vivo gene delivery with mannosylated lipoplex via the intraperitoneal route. J Pharmacol Exp Ther 2006;318:828-834
86. Kawakami S, Sato A, Nishikawa M, et al. Mannose receptor-mediated gene transfer into macrophages using novel mannosylated cationic liposomes. Gene Ther 2000;7:292-299
87. Kawakami S, Wong J, Sato A, et al. Biodistribution characteristics of mannosylated, fucosylated, and galactosylated liposomes in mice. Biochim et Biophys Acta 2000;1524:258-265
88. Opanasopit P, Sakai M, Nishikawa M, et al. Inhibition of liver metastasis by targeting of immunomodulators usingmannosylated liposome carriers. J Control Release 2002;80:283-294
89. Wijagkanalan W, Kawakami S, Takenaga M, et al. Efficient targeting to alveolar macrophages by intratracheal administration of mannosylated liposomes in rats. J Control Release 2008;125:121-130
90. Largent BL, Walton KM, Hoppe CA, et al. Carbohydrate-specific adhesion of alveolar macrophages to mannose-derivatized surfaces. J Biol Chem 1984;259:1764-1769
91. Moreira JN, Hansen CB, Gaspar R, et al. A growth factor antagonist as a targeting agent for sterically stabilized liposomes in human small cell lung cancer. Biochim Biophys Acta 2001;1514:303-317
92. Zhang LJ, Xing B, Wu J, et al. Biodistribution in mice and severity of damage in rat lungs following pulmonary delivery of 9-nitrocamptothecin liposomes. Pulm Pharmacol Ther 2008;21:239-246
93. Mylonakis N, Athanasiou A, Ziras N, et al. Phase II study of liposomal cisplatin (LipoplatinTM) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer. Lung Cancer 2010;68(2):240-247
94. Trammer B, Amann A, Ukomadu EH, et al. Comparative permeability and diffusion kinetics of cyclosporine A liposomes and propylene glycol solution from human lung tissue into human blood ex-vivo. Eur J Pharmacol Biopharm 2008;70:758-764
95. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta 1995;1233:134-144
96. Waldrep JC, Arppe J, Jansa KA, et al. High dose cyclosporin A and budesonide-liposome aerosols. Int J Pharm 1997;152:27-36
97. Iinuma H, Maruyama K, Okinaga K, et al. Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer 2002;99:130-137
98. Singh M. Transferrin as a targeting ligand for liposomes and anticancer drugs. Curr Pharm Des 1999;5:443-451
99. Takada M, Yuzuriha T, Katayama K, et al. Increased lung uptake of liposomes coated with polysaccharides. Biochim Biophys Acta 1984;802:237-244
100. Moreira JN, Gaspar R, Allen TM. Targeting stealth liposomes in a murine model of human small cell lung cancer. Biochim Biophys Acta 2001;1515:167-176
101. Asaia T, Shutob S, Matsudab A, et al. Targeting and anti-tumor efficacy of liposomal 5¢-O-dipalmitoylphosphatidyl 2¢-C-cyano-2¢-deoxy-1- beta-D-arabinopentofuranosylcytosine in mice lung bearing B16BL6 melanoma. Cancer Lett 2001;162:49-56
102. Matsuda A, Nakajima Y, Azuma A, et al. Synthesis of a new potent antitumor nucleoside 2¢-C-cyano-2¢ deoxy-1-beta-D-arabino- pentofuranosylcytosine. Nucleic Acids Symp 1990;22:51-52
103. Matsuda A, Nakajima Y, Azuma A, et al. Nucleosides and nucleotides 100. 2¢-C-cyano-2¢-deoxy-1-beta-D-arabinopentofuranosylcytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside. J Med Chem 1991;34:2917-2919
104. Hayakawa Y, Kawai R, Otsuki K, et al. Evidence supporting the activity of 2¢-Ccyano-2¢-deoxy-1-beta-D-arabinopentofuranosylcytosine as a terminator in enzymatic DNA-chain elongation. Bioorg Med Chem Lett 1998;8:2559-2562
105. Chono S, Tanino T, Seki T, et al. Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections. J Control Release 2008;127:50-58
106. Zaru M, Manca ML, Fadda AM, et al. Chitosan-coated liposomes for delivery to lungs by nebulisation. Colloids Surf Biointerfaces 2009;71:88-95
107. Schijelers RM, Bakker-Woudenberg IAJM, Storm G. Localization of sterically stabilized liposomes in experimental rat Klebsiella pneumoniae pneumonia: dependence on circulation kinetics and presence of poly(ethylene)glycol coating. Biochim Biophys Acta 2000;1468:253-261
108. Abraham AM, Walubo A. The effect of surface charge on the disposition of liposome-encapsulated gentamicin to the rat liver, brain, lungs and kidneys after intraperitoneal administration. Int J Antimicrobiol Agents 2005;25:392-397
109. Gajbhiye V, Kumar PV, Tekade RK, et al. Dendrimers as therapeutic agents: a systematic review. J Pharm Pharmacol 2009;61:989-1003
110. Gajbhiye V, Kumar PV, Tekade RK, et al. Pharmaceutical and biomedical potential of PEGylated dendrimers. 2007;13:415-429
111. Gajbhiye V, Kumar PV, Sharma A, et al. PEGylated PPI dendritic architectures for sustained delivery of anti-inflammatory agent. Curr Nanosci 2008;4:267-277
112. Gajbhiye V, Kumar PV, Sharma A, et al. Dendrimer mediated transdermal & oral delivery of bioactives. Ind J Pharm Sci 2008;70:431-439
113. Gajbhiye V, Kumar PV, Tekade RK, et al. PEGylated PPI dendritic architectures for sustained delivery of H2 receptor antagonist. Eur J Medi Chem 2009;44:1155-1156
114. El-Sayed M, Rhodes CA, Ginski M, et al. Transport mechanism (s) of poly (amidoamine) dendrimers across Caco-2 cell monolayers. Int J Pharm 2003;262:151-157
115. Papagiannaros A, Dimas K, Papaioannou GH, et al. Doxorubicin-PAMAM dendrimer complex attached to liposomes: cytotoxic studies against human cancer cell lines. Int J Pharm 2005;302:29-38
116. Perumal OP, Inapagolla R, Kannan S, et al. The effect of surface functionality on cellular trafficking of dendrimers. Biomaterials 2008;29:3469-3476
117. Kukowska-Latallo JF, Chen C, Eichman J, et al. Enhancement of dendrimer-mediated transfection using synthetic lung surfactant exosurf neonatal in vitro. Biochem Biophys Res Commun 1999;264:253-261
118. Kumar PV, Asthana A, Dutta T, et al. Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers. J Drug Target 2006;14:546-556
119. Kumar PV. PhD Thesis entitled 'Dendritic architecture for the delivery of some anti-tubercular bioactives', Dr. Harisingh Gour University, Sagar 470003 [India], 2007
120. Kannan RM, Inagopalla R, Kannan S, et al. Aiche annual meeting. Dendrimer-based nanodevices for asthma drug delivery: synthesis, in vitro and in vivo studies. Cincinnati:15015 poster session. Drug Gene Deliv 2005
121. Elfinger M, Maucksch C, Rudolph C. Characterization of lactoferrin as a targeting ligand for nonviral gene delivery to airway epithelial cells. Biomaterials 2007;28:3448-3455
122. Zhang JQ, Lu B. Studies on lung targeted niosomes of carboplatin. Acta Pharm Sin 2001;36:303-306
123. Gude RP, Jadhav MG, Rao SGA, et al. Effects of niosomal cisplatin and combination of the same with theophylline and with activated macrophages in murine B16F10 melanoma model. Cancer Biother Radiopharm 2002;17:183-192
124. Jain CP, Vyas SP, Preparation and characterization of niosomes containing rifampicin for lung targeting. J Microencapsul 1995;12:401-407